Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Alzheimers disease (Melatonin - Alzheimers disease)

Records returned : 3 (on 29 May 2025 at 13:33:45). Return to search results for ' Alzheimers disease '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

 
Links :
SPC
NFD1
NICE
Indication :
Status :
See narrative
Formulations :
  • Intravenous infusion
Restrictions / Comments:

Important

This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here  (for a similar drug called lecanemab) which provides advice on potential adverse effects.

 
Links :
SPC
NFD2
Indication :
Status :
See narrative
Formulations :
  • Intravenous infusion
Restrictions / Comments:

Important
Important safety information - see narrative by clicking on the drug name

Lecanemab used in Alzheimer’s disease is currently not available in the NHS. Eisai (the manufacturer and market authorisation holder for lecanemab (Leqembi®)) has started to make the drug available for patients to access through independent sector clinics.
 

The information from NHSE here provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).

 
Links :
SPC
NFD2